Reactivation of human gammaherpesvirus 4, more commonly known as Epstein-Barr Virus, following a period of latent infection has been linked to carcinogenic outcomes, including nasopharyngeal carcinoma, gastric carcinoma, Hodgkin lymphoma, as well as non-cancerous outcomes not limited to multiple sclerosis. The emergence of EBV from its dormant stage to activity is characterized by reactivation of the BZLF1 gene which coordinates the viral transition from the the latent phase to the lytic phase. This study attempts to develop siRNA inhibitors targeting the BZLF1 protein. Eight siRNA candidates, were designed via target-accessibility-centric and structure-centric criteria. They were then assessed for secondary structure formation, mRNA-siRNA duplex stability, possible off-target effects, etc. Optimal siRNAs were found to be B1S2, B1S2, and B6S1, based on optimal scoring across all assessed attributes.